Investor Regeneron Pharmaceuticals Inc
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Regeneron Pharmaceuticals Inc . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2023-09-27 13D/A DBTX / Decibel Therapeutics Inc 2,097,314 100
2023-08-18 13D DBTX / Decibel Therapeutics Inc 2,097,314 2,097,314
2022-02-11 13G DBTX / Decibel Therapeutics Inc 2,097,314
2022-02-11 13G/A ADVM / Adverum Biotechnologies, Inc. 1,809,098 1,809,098
2022-02-11 13G/A NTLA / Intellia Therapeutics, Inc. 2,777,777 3,702,995
2016-05-11 13G NTLA / Intellia Therapeutics, Inc. 2,777,777
2014-08-07 13G ADVM / Adverum Biotechnologies, Inc. 1,809,098